Need Help?

Immunological hallmarks for clinical response to BCG in bladder cancer

Intravesical Bacillus Calmette-Guerin (BCG) is an effective immunotherapy for non-muscle invasive bladder cancer (NMIBC). However, recurrence and progression remain frequent warranting deeper insights into its mechanism. We herein comprehensively profiled blood and tissues obtained from NMIBC patients before, during and after BCG treatment using cytometry by time-of-flight (CyTOF) and RNA sequencing to identify the key immune subsets crucial for anti-tumour activity.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001006634 Illumina HiSeq 4000 16
Publications Citations
Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Front Immunol 11: 2020 615091